[Statistical evaluation of a cooperative study toward investigation of the effectiveness of the coronary stimulant dilazep in ischemic heart disease. 3. Influence of the duration of therapy and co-medication on the therapeutic result. Secondary effects and discontinuation of therapy].
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000150:complications; D001381:Azepines / Q000009:adverse effects / Q000627:therapeutic use*; D001565:Benzoates / Q000009:adverse effects / Q000627:therapeutic use; D002301:Cardiac Glycosides / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000150:complications / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D004812:Epidemiologic Methods; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009574:Nitro Compounds / Q000627:therapeutic use; D013997:Time Factors; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D001381:Azepines; D001565:Benzoates; D002301:Cardiac Glycosides; D009574:Nitro Compounds; D014665:Vasodilator Agents
Statistische Auswertung einer Gemeinschaftsstudie zur Untersuchung der Wirksamkeit des Koronartrainers Dilazep bei ischämischen Herzerkrankungen. 3. Mitteilung: Einfluss von Therapiedauer und Komedikation auf das Behandlungsergebnis. Nebenwirkungen und Therapieabbrüche